• Basilea Pharmaceutica will present new fosmanogepix, isavuconazole and ceftobiprole data at IDWeek 2026, October 21-24, in Washington, D.C.
• Phase 3 antifungal fosmanogepix presentations on October 23 will cover pediatric expanded-access experience in invasive mold infections and manogepix activity against Candida auris.
• Other research will examine isavuconazole safety and treatment use, alongside ceftobiprole dosing and evidence supporting pediatric use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200115PRIMZONEFULLFEED1001278790) on October 20, 2026, and is solely responsible for the information contained therein.